Author(s):
Gholam Basati, Hamed Sepahvand, Pardis Ghanadi, Saber Abbaszadeh, Mehrnoosh Sedighi
Email(s):
M.Sedighi63@ymail.com
DOI:
10.5958/0974-360X.2020.00710.6 
Address:
Gholam Basati1, Hamed Sepahvand2, Pardis Ghanadi3, Saber Abbaszadeh4,5, Mehrnoosh Sedighi6*
1Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran.
2Master of Science (MSc) in Surgery/Internal, Emergency Department Nurse, Khorramabad University of Lorestan, Iran.
3Medical Student, Lorestan University of Medical Sciences, Khorramabad, Iran.
4Department of Biochemistry, Lorestan University of Medical Sciences, Khorramabad, Iran.
5Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
6Cardiovascular Research Center, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khoramabad, Iran.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
The main purpose of this study was to review and introduce the physical and pharmacological stimuli and their potential effects with respect to the pharmacological impacts of preconditioning (PC) in cardiovascular and ischemia clinical studies. In this review, data were retrieved from the Information Sciences Institute, PubMed, Scientific Information Database, and Scopus databases, with a further emphasis on the articles published in the last 10 years. Key words used for this purpose included ischemia, reperfusion, heart, infarction, and preconditioning. The eligible and relevant clinical trials on pharmacological stimuli were included in this review. The relevant articles, all have been published from 1983 - 2016. Today, many studies are being performed to implement and apply PC in clinical human cases, in order to minimize the ischemia reperfusion (IR)-induced complication in certain conditions such as myocardial infarction and heart surgery. The Drugs used in the studies are mostly common agents such as nitroglycerin, oxygen, adenosine, etc., and are among commonly used drugs in cardiovascular diseases, which often increase tissue resistance, and conveniently used in the patient's bedside and are accepted by the patients. Using a physical or pharmacological stimulus before prolonged ischemia increases tissue resistance by activating intracellular mechanisms, thereby reducing the IR-induced, cardiac damage and erythema.
Cite this article:
Gholam Basati, Hamed Sepahvand, Pardis Ghanadi, Saber Abbaszadeh, Mehrnoosh Sedighi. Pharmacology for Preconditioning in Clinical Studies. Research J. Pharm. and Tech. 2020; 13(8):4015-4022. doi: 10.5958/0974-360X.2020.00710.6
Cite(Electronic):
Gholam Basati, Hamed Sepahvand, Pardis Ghanadi, Saber Abbaszadeh, Mehrnoosh Sedighi. Pharmacology for Preconditioning in Clinical Studies. Research J. Pharm. and Tech. 2020; 13(8):4015-4022. doi: 10.5958/0974-360X.2020.00710.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-8-83
REFERENCES:
1. Sedighi M, Bahmani M, Asgary S, Beyranvand F, Rafieian-Kopaei M. A review of plant-based compounds and medicinal plants effective on atherosclerosis. Journal of research in medical sciences: the official Journal of Isfahan University of Medical Sciences. 2017;22.
2. Moens A, Claeys M, Timmermans J, Vrints C. Myocardial ischemia/ reperfusion-injury, a clinical view on a complex pathophysiological process. International Journal of Cardiology. 2005; 100(2): 179-190.
3. Yellon D, Alkhulaifi A, Pugsley W. Preconditioning the human myocardium. The Lancet. 1993;342(8866):276-277.
4. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. Journal of Molecular and Cellular Cardiology. 1984; 16(6): 497-518.
5. Tzivoni D, Keren A, Granot H, Gottlieb S, Benhorin J, Stern S. Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal's angina. American Heart Journal. 1983;105(2):323-325.
6. Paranskaya L, Akin I, Chatterjee T, Ritz A, Paranski P, Rehders T, Ince H, Schneider H, Nienaber CA, Bänsch D. Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy. Herzschrittmachertherapie+ Elektrophysiologie. 2011;22(4):243-248.
7. Peart JN, Headrick JP. Sustained cardioprotection: exploring unconventional modalities. Vascular Pharmacology. 2008;49(2):63-70.
8. Kloner RA, Przyklenk K, Whittaker P, Hale S. Preconditioning stimuli and inadvertent preconditioning. In.: Elsevier; 1995.
9. Zaugg M, Lucchinetti E, Uecker M, Pasch T, Schaub M. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. British Journal of anaesthesia. 2003;91(4):551-565.
10. Sanada S, Kitakaze M. Ischemic preconditioning: emerging evidence, controversy, and translational trials. International Journal of Cardiology. 2004; 97(2):263-276.
11. Ovize M, Kloner RA, Przyklenk K. Stretch preconditions canine myocardium. American Journal of Physiology-Heart and Circulatory Physiology. 1994;266(1):H137-H146.
12. Xiao C-Y, Hara A, Yuhki K-i, Fujino T, Ma H, Okada Y, Takahata O, Yamada T, Murata T, Narumiya S. Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation. 2001;104(18):2210-2215.
13. Hearse DJ. Myocardial ischaemia: can we agree on a definition for the 21st century? Cardiovascular Research. 1994;28(12):1737-1744.
14. Garlid KD, Dos Santos P, Xie Z-J, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2003;1606(1):1-21.
15. Sommerschild HT, Kirkebøen KA. Preconditioning− endogenous defence mechanisms of the heart. Acta anaesthesiologica scandinavica. 2002; 46(2): 123-137.
16. Appelshäuser H, Bächler J, Bailey S, Barnby L, Bartke J, Barton R, Białkowska H, Billmeier A, Blyth C, Bock R. Baryon stopping and charged particle distributions in central P b+ P b collisions at 158 GeV per nucleon. Physical Review Letters. 1999; 82(12):2471.
17. M. N. Death show in 23 provinces of the country. 2004. Fourth Book Ministry of Public Health, Tehran. 2006.
18. de Jong JW, de Jonge R, Keijzer E, Bradamante S. The role of adenosine in preconditioning. Pharmacology and Therapeutics. 2000;87(2):141-149.
19. Light PE, Bladen C, Winkfein RJ, Walsh MP, French RJ. Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels. Proceedings of the National Academy of Sciences. 2000; 97(16):9058-9063.
20. Downey JM, Krieg T, Cohen MV. Mapping preconditioning's signaling pathways. Annals of the New York Academy of Sciences. 2008; 1123(1): 187-196.
21. Gustafsson ÅB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovascular Research. 2007;77(2):334-343.
22. Liu YN, Zhou ZM, Chen P. Evidence that hydroxysafflor yellow A protects the heart against ischaemia–reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Clinical and Experimental Pharmacology and Physiology. 2008;35(2):211-216.
23. Di Lisa F, Bernardi P. Mitochondria and ischemia–reperfusion injury of the heart: fixing a hole. Cardiovascular Research. 2006;70(2):191-199.
24. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia‐reperfusion injury and preconditioning. British Journal of Pharmacology. 2003;138(4):532-543.
25. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circulation Research. 2004;94(1):7-16.
26. Baines CP, Liu GS, Birincioglu M, Critz SD, Cohen MV, Downey JM. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. American Journal of Physiology-Heart and Circulatory Physiology. 1999;276(4):H1361-H1368.
27. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88(3):1264-1272.
28. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovascular Research. 2002;55(3):534-543.
29. Korge P, Honda HM, Weiss JN. Protection of cardiac mitochondria by diazoxide and protein kinase C: implications for ischemic preconditioning. Proceedings of the National Academy of Sciences. 2002;99(5):3312-3317.
30. de Waard MC, van Haperen R, Soullié T, Tempel D, de Crom R, Duncker DJ. Beneficial effects of exercise training after myocardial infarction require full eNOS expression. Journal of Molecular and Cellular Cardiology. 2010; 48(6): 1041-1049.
31. Hoffman JI. The natural and unnatural history of congenital heart disease: John Wiley and Sons; 2011.
32. Karu I, Loit R, Zilmer K, Kairane C, Paapstel A, Zilmer M, Starkopf J. Pre‐treatment with hyperoxia before coronary artery bypass grafting–effects on myocardial injury and inflammatory response. Acta Anaesthesiologica Scandinavica. 2007;51(10):1305-1313.
33. Karu I, Tähepõld P, Ruusalepp A, Zilmer K, Zilmer M, Starkopf J. Effects of 60 minutes of hyperoxia followed by normoxia before coronary artery bypass grafting on the inflammatory response profile and myocardial injury. Journal of Negative Results in Biomedicine. 2012;11(1):14.
34. Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Hyperbaric oxygen preconditioning improves myocardial function, reduces length of intensive care stay, and limits complications post coronary artery bypass graft surgery. Cardiovascular Revascularization Medicine. 2010; 11(1): 8-19.
35. Mohammadi A, Raoufi S, Namdari M, Raoufi A, Anbari K, Tahzibi S, Almasian M, Rasoulian B. Pre-Exposure to Normobaric Hyperoxia Has No Effect on Myocardial Injury Biomarkers after Percutaneous Transluminal Coronary Angioplasty. Iranian Heart Journal. 2016;17(3):18-26.
36. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation. 1997;95(11):2500-2507.
37. Wei M, Kuukasjärvi P, Laurikka J, Pehkonen E, Kaukinen S, Laine S, Tarkka M. Cytokine responses in patients undergoing coronary artery bypass surgery after ischemic preconditioning. Scandinavian Cardiovascular Journal. 2001;35(2):142-146.
38. Wang Y, Shen J, Xiong X, Xu Y, Zhang H, Huang C, Tian Y, Jiao C, Wang X, Li X. Remote ischemic preconditioning protects against liver ischemia-reperfusion injury via heme oxygenase-1-induced autophagy. PloS one. 2014;9(6): e98834.
39. Lee T-M, Su S-F, Chou T-F, Tsai C-H. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. American Journal of Cardiology. 2001;88(10):1108-1113.
40. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. Journal of the American College of Cardiology. 1999;34(3):639-650.
41. Carr CS, Hill RJ, Masamune H, Kennedy SP, Knight DR, Tracey WR, Yellon DM. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischemia. Cardiovascular Research. 1997; 36(1):52-59.
42. Kerensky RA, Kutcher MA, Braden GA, Applegate RJ, Solis GA, Little WC. The effects of intracoronary adenosine on preconditioning during coronary angioplasty. Clinical Cardiology. 1995;18(2):91-96.
43. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. Journal of the American College of Cardiology. 1996;28(5):1119-1126.
44. Schaefer S, Correa SD, Valente RJ, Laslett LJ. Blockade of adenosine receptors with aminophylline limits ischemic preconditioning in human beings. American Heart Journal. 2001;142(3):5A-9A.
45. Kiani AA, Babaei F, Sedighi M, Soleimani A, Ahmadi K, Shahrokhi S, Anbari K, Nazari A. CXCR4 expression is associated with time–course permanent and temporary myocardial infarction in rats. Iranian Journal of Basic Medical Sciences. 2017;20(6):648.
46. Belhomme D, Peynet J, Louzy M, Launay J-M, Kitakaze M, Menasché P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation. 1999;100(suppl 2): II-340-Ii-344.
47. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C, Desideri G, Chiariello L, Gioffré PA. Effects of naloxone on myocardial ischemic preconditioning in humans. Journal of the American College of Cardiology. 1999; 33(7):1863-1869.
48. Yang J, Zhang J, Cui W, Liu F, Xie R, Yang X, Gu G, Zheng H, Lu J, Yang X. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatolian Journal of Cardiology. 2015; 15(2):125.
49. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris. Japanese Heart Journal. 2002;43(5):443-453.
50. Matsuo H, Watanabe S, Yasuda S, Hirose T, Iwama M, Tanaka S, Yamaki T, Ono K, Takahashi H, Segawa T. Myocardial perfusion during transient slow‐flow in the patient with old vein graft intervention: Assessment by serial measurement of pressure‐derived fractional flow reserve and thermodilution‐derived coronary flow reserve. Catheterization and Cardiovascular Interventions. 2003;60(3):392-398.
51. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circulation Journal. 2002; 66(4): 317-322.
52. Kato T, Kamiyama T, Maruyama Y, Tanaka S, Yoshimoto N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. American Heart Journal. 2001;141(6):940-943.
53. Das M, Das DK. Molecular Mechanism of Preconditioning. IUBMB life. 2008; 60(4):199-203.
54. Zhang H, McPherson B, Liu H, Baman T, Rock P, Yao Z. H< sub> 2. Am J Physiol Heart Circ Physiol 282 (4): H1395-H1403. 2002.
55. Mantel C, Messina-Graham SV, Broxmeyer HE. Superoxide flashes, reactive oxygen species, and the mitochondrial permeability transition pore: potential implications for hematopoietic stem cell function. Current Opinion in Hematology. 2011;18(4):208-213.
56. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-1136.
57. Liu X-q, Sheng R, Qin Z-h. The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacologica Sinica. 2009;30(8):1071.
58. Endre ZH. Renal ischemic preconditioning: finally some good news for prevention of acute kidney injury. Kidney International. 2011;80(8):796-798.
59. Heusch G. Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? In.: Am Heart Assoc; 2001.
60. Lee T-M, Su S-F, Chou T-F, Tsai C-H. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. The American Journal of Cardiology. 2001;88(10):1108-1113.
61. Yang J, Zhang J, Cui W, Liu F, Xie R, Yang X, Gu G, Zheng H, Lu J, Yang X. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatolian Journal of Cardiology/ Anadolu Kardiyoloji Dergisi. 2015;15(2).
62. Illes RW, Swoyer KD. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent cold blood cardioplegia. The Annals of Thoracic Surgery. 1998;65(3):748-752.
63. Ferguson TB. Ischemia/reperfusion injury in coronary artery bypass grafting: Time to revisit? The Journal of Thoracic and Cardiovascular Surgery. 2011;141(1):1-2.
64. PARK JW, Braun P, Mertens S, Heinrich K. Ischemia: reperfusion injury and restenosis after coronary angioplasty. Annals of the New York Academy of Sciences. 1992;669(1):215-236.
65. Eisen A, Fisman EZ, Rubenfire M, Freimark D, McKechnie R, Tenenbaum A, Motro M, Adler Y. Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis. 2004;172(2):201-210.
66. Gidday JM. Pharmacologic preconditioning: translating the promise. Translational Stroke Research. 2010;1(1):19-30.
67. Rasoulian B, Mohammad Hosseniakbari H, Kadkhodaee M, Mofid M, Baqeri G, Bigdeli MR, Ghasemi A, Mohebbi HA, Asgari A, Khoshbaten A. Preconditioning with oxygen attenuates rat renal ischemia–reperfusion injury. Journal of Surgical Research. 2008;146(2):282-288.
68. Cohen MV, Yang X-M, Liu GS, Heusch G, Downey JM. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circulation Research. 2001;89(3):273-278.